Avanza Fonder’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.57M Buy
76,105
+9,811
+15% +$872K 0.13% 145
2026
Q2
$6M Sell
66,294
-971
-1% -$81.3K 0.13% 152
2026
Q1
$5.39M Sell
67,265
-5,778
-8% -$476K 0.15% 137
2025
Q4
$6.23M Buy
73,043
+1,309
+2% +$107K 0.16% 126
2025
Q3
$5.58M Buy
71,734
+9,173
+15% +$717K 0.14% 126
2025
Q2
$4.89M Sell
62,561
-141
-0.2% -$10.5K 0.14% 124
2025
Q1
$4.52M Sell
62,702
-2,740
-4% -$196K 0.15% 128
2024
Q4
$4.84M Buy
+65,442
New +$4.58M 0.14% 123

Other funds holding EW

Avanza Fonder's EW Position: Q3 2026 in Review

Avanza Fonder increased its Edwards Lifesciences (EW) stake by 15% in Q3 2026, buying an estimated $872K and bringing the position to 76,105 shares worth $6.57M. The position accounts for 0.13% of the portfolio, ranked #145.

Avanza Fonder first reported a position in EW in Q4 2024 and has held it in 8 quarters since. 1,342 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Avanza Fonder held 76,105 shares of Edwards Lifesciences worth $6.57M as of Q3 2026.
  • Avanza Fonder bought 9,811 Edwards Lifesciences shares in Q3 2026, an estimated $872K.
  • Edwards Lifesciences made up 0.13% of Avanza Fonder's portfolio in Q3 2026, its #145 holding.
  • Avanza Fonder first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 8 quarters since.
  • 1,342 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Avanza Fonder's 13F filing for Q3 2026, filed 13 Oct 2026.